[Electrophysiologic remodeling and drug treatment of atrial fibrillation].
Since 1995, a number of studies have established and detailed the mechanisms of electrical and structural atrial remodeling induced by atrial fibrillation. Atrial remodeling involves many cellular components, from ionic channels to connexins. The determination of these mechanisms may help to define a new therapeutic targets of atrial fibrillation, a frequent arrhythmia that remains difficult to treat. Atrial remodeling prevention may lead to limit the evolution of the arrhythmia (early recurrences after reduction, AF secondary to atrial tachycardia, permanent AF, decrease in atrial contractility, sinus dysfunction). Except amiodarone, the usual antiarrhythmic drugs have no effect on atrial remodeling. Calcium channel inhibitors prevent early remodeling but have no effect on prolonged remodeling. Digoxin increases remodeling. Angiotensin II receptor inhibitors have been shown to prevent early AF recurrence after reduction and are very promising in such a direction. Other methods such as the one of antioxidant therapy seem to be promising and could define soon a new antiarrhythmic therapeutic class, the antiremodeling drugs.
Piot
O
O
Département de rythmologie, centre cardiologique du Nord, 32-36, rue des Moulins-Gémeaux, 93207 Saint-Denis, France. o.piot@ccncardio.com
Copie
X
X
Lascault
G
G
D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans